For example, Nurix is going to file an IND application with the FDA at the end of this year to test its BTK PROTAC in patients with B cell malignancies (https://www.nurixtx.com/research-development/pipeline/), Kymera is advancing a STAT3 PROTAC as one of their drug candidates in oncology (https://www.kymeratx.com/pipeline/), and Dialectic Therapeutics (DT) is pursuing preclinical development of the Bcl-xL PROTAC DT2216 for the treatment of hematologic malignancies and solid cancer tumors in 2021 (https://www.dtsciences.com/#science). The gene discussed is STAT3; the disease is hematologic disorder.